RU2015151175A - Способы улучшения липидных профилей с применением атрасентана - Google Patents

Способы улучшения липидных профилей с применением атрасентана Download PDF

Info

Publication number
RU2015151175A
RU2015151175A RU2015151175A RU2015151175A RU2015151175A RU 2015151175 A RU2015151175 A RU 2015151175A RU 2015151175 A RU2015151175 A RU 2015151175A RU 2015151175 A RU2015151175 A RU 2015151175A RU 2015151175 A RU2015151175 A RU 2015151175A
Authority
RU
Russia
Prior art keywords
subject
level
baseline
relative
approximately
Prior art date
Application number
RU2015151175A
Other languages
English (en)
Russian (ru)
Inventor
КРЕСПО Блас КОЛЛ
Деннис АНДРЕСС
Питер Дж. БРЕННАН
Джеймс К. ШТОЛЬЦЕНБАХ
Original Assignee
Эббви, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эббви, Инк. filed Critical Эббви, Инк.
Publication of RU2015151175A publication Critical patent/RU2015151175A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2015151175A 2013-04-30 2014-04-30 Способы улучшения липидных профилей с применением атрасентана RU2015151175A (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361817645P 2013-04-30 2013-04-30
US61/817,645 2013-04-30
US201361824199P 2013-05-16 2013-05-16
US61/824,199 2013-05-16
PCT/US2014/036152 WO2014179453A1 (en) 2013-04-30 2014-04-30 Methods for improving lipid profiles using atrasentan

Publications (1)

Publication Number Publication Date
RU2015151175A true RU2015151175A (ru) 2017-06-07

Family

ID=50928265

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015151175A RU2015151175A (ru) 2013-04-30 2014-04-30 Способы улучшения липидных профилей с применением атрасентана

Country Status (13)

Country Link
US (1) US9855245B2 (enExample)
EP (1) EP2991680A1 (enExample)
JP (1) JP2016521279A (enExample)
KR (1) KR20160003128A (enExample)
CN (1) CN105246512A (enExample)
AU (1) AU2014259961A1 (enExample)
BR (1) BR112015027631A2 (enExample)
CA (1) CA2909871A1 (enExample)
HK (1) HK1221916A1 (enExample)
MX (1) MX2015015036A (enExample)
RU (1) RU2015151175A (enExample)
SG (1) SG11201508960SA (enExample)
WO (1) WO2014179453A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX366925B (es) 2010-11-04 2019-07-31 Albireo Ab Inhibidores de ibat para el tratamiento de enfermedades hepaticas.
CA2952406A1 (en) 2014-06-25 2015-12-30 Ea Pharma Co., Ltd. Solid formulation and method for preventing or reducing coloration thereof
JP6954927B2 (ja) 2016-02-09 2021-10-27 アルビレオ・アクチボラグ 経口コレスチラミン製剤及びその使用
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
SG11202108566VA (en) 2019-02-06 2021-09-29 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
HRP20260121T1 (hr) 2019-12-17 2026-03-13 Chinook Therapeutics, Inc. Farmaceutski prihvatljiva sol atrasentana za uporabu u postupku za liječenje iga nefropatije
US20230270718A1 (en) * 2020-04-10 2023-08-31 Chinook Therapeutics, Inc. Methods of treating diabetic kidney disease

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2799241A (en) 1949-01-21 1957-07-16 Wisconsin Alumni Res Found Means for applying coatings to tablets or the like
US3173876A (en) 1960-05-27 1965-03-16 John C Zobrist Cleaning methods and compositions
NL271831A (enExample) 1960-11-29
US3276586A (en) 1963-08-30 1966-10-04 Rosaen Filter Co Indicating means for fluid filters
US3546142A (en) 1967-01-19 1970-12-08 Amicon Corp Polyelectrolyte structures
US3541006A (en) 1968-07-03 1970-11-17 Amicon Corp Ultrafiltration process
US3541005A (en) 1969-02-05 1970-11-17 Amicon Corp Continuous ultrafiltration of macromolecular solutions
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4077407A (en) 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4200098A (en) 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US5286497A (en) 1991-05-20 1994-02-15 Carderm Capital L.P. Diltiazem formulation
US5573776A (en) 1992-12-02 1996-11-12 Alza Corporation Oral osmotic device with hydrogel driving member
US5544163A (en) 1994-03-08 1996-08-06 Excel, Inc. Expandable telecommunications system
US6162927A (en) 1994-08-19 2000-12-19 Abbott Laboratories Endothelin antagonists
US6946481B1 (en) 1994-08-19 2005-09-20 Abbott Laboratories Endothelin antagonists
US7365093B2 (en) 1994-08-19 2008-04-29 Abbott Laboratories Endothelin antagonists
US7208517B1 (en) 1994-08-19 2007-04-24 Abbott Labortories Endothelin antagonists
US5767144A (en) 1994-08-19 1998-06-16 Abbott Laboratories Endothelin antagonists
CN1072649C (zh) 1995-09-13 2001-10-10 武田药品工业株式会社 苯并氧杂吖庚因化合物,其生产方法和用途
CL2004000545A1 (es) * 2003-03-18 2005-01-28 Pharmacia Corp Sa Organizada B Uso de un antagonista de los receptores de aldosterona y un antagonista de receptores de endotelina para el tratamiento o profilaxis de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopatia y enfermedades cardiovascul
US20060189675A1 (en) 2004-09-17 2006-08-24 Steve King Crystalline form of a drug
WO2006034084A1 (en) 2004-09-17 2006-03-30 Abbott Laboratories Crystalline form 2 of atrasentan hydrochloride
WO2006034234A1 (en) 2004-09-17 2006-03-30 Abbott Laboratories Crystalline form 3 of atrasentan hydrochloride
WO2006034085A1 (en) 2004-09-17 2006-03-30 Abbott Laboratories Crystalline form of atrasentan hydrochloride
US20070004745A1 (en) * 2005-03-25 2007-01-04 Schering-Plough Corporation Methods of treating benign prostatic hyperplasia or lower urinary tract symptoms by using PDE 5 inhibitors
US20080132710A1 (en) 2006-12-04 2008-06-05 Abbott Laboratories Atrasentan hydrochloride crystalline form 2
CA2697057A1 (en) 2007-08-22 2009-02-26 Gilead Colorado, Inc. Therapy for complications of diabetes
CN101822837A (zh) * 2010-02-02 2010-09-08 王丽燕 包含艾力沙坦酯盐的药物组合物
JP2016512201A (ja) 2013-03-08 2016-04-25 アッヴィ・インコーポレイテッド 急性腎障害の治療方法

Also Published As

Publication number Publication date
WO2014179453A1 (en) 2014-11-06
HK1221916A1 (zh) 2017-06-16
SG11201508960SA (en) 2015-11-27
BR112015027631A2 (pt) 2017-08-22
US9855245B2 (en) 2018-01-02
US20160074363A1 (en) 2016-03-17
JP2016521279A (ja) 2016-07-21
AU2014259961A1 (en) 2015-11-05
CN105246512A (zh) 2016-01-13
EP2991680A1 (en) 2016-03-09
MX2015015036A (es) 2016-02-09
KR20160003128A (ko) 2016-01-08
CA2909871A1 (en) 2014-11-06

Similar Documents

Publication Publication Date Title
JP2016521279A5 (enExample)
MY199017A (en) Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or an anti-adm non-ig scaffold for use in therapy
IL274403A (en) Tyrosine hydroxylase inhibitors for the treatment of intestinal hypertension
WO2012100229A3 (en) Compositions and methods for cardiovascular disease
EA201391236A1 (ru) Новые циклические производные азабензимидазола, используемые в качестве антидиабетических агентов
HK1204271A1 (en) Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
JP2014516953A5 (enExample)
RU2015110240A (ru) Ингибиторы nep для лечения заболеваний, характеризующихся увеличением или ремоделированием предсердия
WO2011055944A3 (en) Methods for treating fibromyalgia syndrome
JP2016523847A5 (enExample)
JP2016538254A5 (enExample)
EA201291247A1 (ru) ФАРМАЦЕВТИЧЕСКИЙ СОСТАВ В ФОРМЕ ДВУХСЛОЙНЫХ ТАБЛЕТОК, СОДЕРЖАЩИХ ИНГИБИТОР HMG-CoA РЕДУКТАЗЫ И ИРБЕСАРТАН
HK1221916A1 (zh) 使用阿曲生坦用於改善脂质概况的方法
DK1713458T5 (da) Fremgangsmåde til forstærkning af biotilgængeligheden af ospemifen
JP2007527433A5 (enExample)
FI3821891T3 (fi) FK506:n käyttö pulmonaarisen valtimohypertension hoidossa
EA200801008A1 (ru) Гипохолестеринемические соединения
Dursun et al. The anti-inflammatory and antioxidant effects of pravastatin and nebivolol in rat aorta.
RU2015127834A (ru) Способы лечения диабета путем введения антагониста рецептора глюкагона в сочетании с ингибитором поглощения холестерина
Martin-Ventura et al. Treatment with amlodipine and atorvastatin has additive effect on blood and plaque inflammation in hypertensive patients with carotid atherosclerosis: New strategies to prevent cardiovascular risk in chronic kidney disease
EA201590474A1 (ru) ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ОСНОВЕ КОМПОЗИТНЫХ КАПСУЛ, ВКЛЮЧАЮЩИХ ИРБЕСАРТАН И ИНГИБИТОР ГМГ-КоА РЕДУКТАЗЫ
EA202092397A3 (ru) Фармацевтическая композиция для подавления образования кзкднк вируса гепатита в
WO2014141295A3 (en) Treatment and prophylaxis of kidney diseases
WO2013121300A3 (en) Methods for treating psoriasis and vascular inflammation
Yagi et al. Effects of statins on cardiorenal syndrome

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20180813